Origin and evaluation of depressed inotropism in hypertensive cardiomyopathy

J F Viallard1, S Bonoron-Adele, P Dos Santos

  • 1INSERM Cardiologie, Bordeaux-Pessac, France.

European Heart Journal
|November 1, 1993
PubMed

Insights

Left ventricular hypertrophy (LVH) impairs heart contractility and relaxation, making it sensitive to ischemia. Treatments blocking the renin-angiotensin or sympathetic nervous systems effectively reverse LVH.

Area of Science:

  • Cardiology
  • Physiology
  • Pathophysiology

Background:

  • Left ventricular pressure overload induces left ventricular hypertrophy (LVH) as an adaptive response.
  • LVH leads to impaired myocardial contractility and relaxation, increasing sensitivity to ischemia and hemodynamic changes.
  • Coronary microvascular alterations contribute to increased vascular resistance in LVH.

Purpose of the Study:

  • To investigate the functional and structural changes in the hypertrophied myocardium due to pressure overload.
  • To explore the impact of LVH on systolic function and coronary hemodynamics.
  • To evaluate the efficacy of different drug classes in reversing LVH.

Main Methods:

  • Experimental studies using papillary muscles and isolated coronary-perfused hearts from renovascular hypertensive rats.
  • Measurement of myocardial contractility, isometric timing, and left ventricular pressure.
  • Analysis of coronary vascular resistance in human and animal models.
  • Assessment of LVH regression with angiotensin-converting enzyme inhibitors, calcium-channel blockers, and beta-blockers.

Main Results:

  • Papillary muscles showed decreased shortening velocity, increased isometric timing, and elevated developed pressure.
  • Isolated hearts exhibited impaired systolic function under major loading conditions.
  • Both human and animal studies indicated increased coronary vascular resistance.
  • Only drugs targeting the renin-angiotensin system or sympathetic nervous system effectively reversed LVH.

Conclusions:

  • LVH significantly impairs myocardial contractility and relaxation, with functional deficits becoming apparent under increased loading.
  • Alterations in coronary microvasculature contribute to increased resistance in LVH.
  • Pharmacological interventions targeting the renin-angiotensin and sympathetic nervous systems are most effective for LVH regression.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...